- Beta blockers
- Vitamin E systemic
- VMAT2 inhibitors (vesicular monoamine transporter-2 inhibitors)
- Dopaminergic agents
Tardive Dyskinesia Treatment Market size was valued at USD 5.68 billion in 2022 and is poised to grow at a CAGR of 4.2% from 2023-2029. Tardive dyskinesia is a neurological condition in which involuntary movements are involved. The phrases tardive and dyskinesia can be defined as delayed and aberrant movement, respectively. Finger movement, facial grimacing, jaw swinging, repetitive chewing, constant blinking of the eyes, tongue pushing, and other symptoms of tardive dyskinesia. Tardive dyskinesia is a side effect of neurotic medications. These drugs are also known as anti psychotics or strong tranquilizers. These medications are mostly used to treat mental illnesses. When you use a drug for months or years, you may develop tardive dyskinesia. Because the drug that can be used to treat tardive dyskinesia has not yet been licences, and the method of treatment has not yet been validated, treating the disease is a challenging undertaking. The patient's neurological system is affected by the tardive dyskinesia treatment. Because the drug that can be used to treat tardive dyskinesia has not yet been licenced, and the method of treatment has not yet been validated, treating the disease is a challenging undertaking. The patient's neurological system is affected by the tardive dyskinesia treatment. this report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition.
Fastest Growing Market
In the approaching years, the market for tardive dyskinesia treatment will expand dramatically. The increasing number of people suffering from neurological problems is a major element driving the tardive dyskinesia therapy market. The majority of the population in North America suffers from tardive dyskinesia, and individuals are eagerly anticipating treatment, driving the market's growth. The approval process for new treatment modalities by the respective association is a stumbling block to market growth.
The tardive dyskinesia treatment market size was valued at USD 5.68 billion in 2022
Biogen (U.S) Teva Pharmaceutical Industries Ltd. (Israel) GlaxoSmithKline Plc.(U.K) Johnson & Johnson Services, Inc.(U.S) Pfizer Inc.(U.S) Neurocrine Biosciences, Inc.(U.S)
The tardive dyskinesia treatment market segments are by drug classes, disorder, and distribution channel